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Abstract: BACKGROUND: Extracorporeal life support (ECLS) as a bridge to lung transplantation
(LuTx) is a promising option for patients with end-stage lung disease on the transplant waiting list.
We investigated the outcome of patients bridged to lung transplantation on ECLS technologies, mainly
extracorporeal membrane oxygenation (ECMO). METHODS: Between January 2007 and October 2013,
ECLS was implanted in 30 patients with intention to bridge to LuTx. Twenty-six patients (26/30) were
successfully bridged to LuTx on ECLS. The most common diagnosis was cystic fibrosis (N = 12). Venove-
nous ECMO was used in 10, venoarterial in 4, interventional lung assist in 5, and stepwise combination
of them in 7 recipients. RESULTS: Two patients weaned from ECMO, and 2 patients died on ECMO
on the waiting list. Median duration of ECLS was 21 days (1-81 years). Six patients were awake and
spontaneously breathing during ECLS support. Thirty-day, 1-year, and 2-year survivals were 89%, 68%,
and 53%, respectively, for bridged patients and 96%, 85%, and 79%, respectively, for control group (P
= 0.001). Three months conditional survivals were 89% and 69% at 1 and 2 years for ECLS group, com-
pared to 92% and 86% for control group (P = 0.03). Cystic fibrosis recipients had 82% survival rate at 1
and 2 years. All recipients bridged to LuTx on awake ECLS (N = 6) are alive with a median follow-up of
10.8 months (range, 6-21 months). CONCLUSIONS: Our data show significantly lower survival in this
high-risk group compared to patients transplanted without preoperative ECLS. Awake and ambulatory
ECLS provides the best prognosis for these high-risk patients.
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Outcome of Extracorporeal Membrane
Oxygenation as a Bridge To Lung Transplantation:
An Institutional Experience and Literature Review
Ilhan Inci,1 Stephanie Klinzing,2 Didier Schneiter,1 Reto A. Schuepbach,3 Peter Kestenholz,1 Sven Hillinger,1
Christian Benden,4 Marco Maggiorini,2 and Walter Weder1
Background.Extracorporeal life support (ECLS) as a bridge to lung transplantation (LuTx) is a promising option for patients with
end-stage lung disease on the transplant waiting list. We investigated the outcome of patients bridged to lung transplantation on
ECLS technologies, mainly extracorporeal membrane oxygenation (ECMO). Methods. Between January 2007 and October
2013, ECLS was implanted in 30 patients with intention to bridge to LuTx. Twenty-six patients (26/30) were successfully bridged
to LuTx on ECLS. The most common diagnosis was cystic fibrosis (N = 12). Venovenous ECMOwas used in 10, venoarterial in 4,
interventional lung assist in 5, and stepwise combination of them in 7 recipients.Results. Two patients weaned from ECMO, and
2 patients died on ECMO on the waiting list. Median duration of ECLS was 21 days (1-81 years). Six patients were awake and
spontaneously breathing during ECLS support. Thirty-day, 1-year, and 2-year survivals were 89%, 68%, and 53%, respectively, for
bridged patients and 96%, 85%, and 79%, respectively, for control group (P = 0.001). Three months conditional survivals were
89% and 69% at 1 and 2 years for ECLS group, compared to 92% and 86% for control group (P = 0.03). Cystic fibrosis recipients
had 82% survival rate at 1 and 2 years. All recipients bridged to LuTx on awake ECLS (N = 6) are alive with a median follow-up of
10.8months (range, 6-21months).Conclusions.Our data show significantly lower survival in this high-risk group compared to pa-
tients transplantedwithout preoperative ECLS. Awake and ambulatory ECLS provides the best prognosis for these high-risk patients.
(Transplantation 2015;99: 1667–1671)
Lung transplantation (LuTx) is an established therapeuticoption for patients with end-stage lung disease.1 Although
the number of lung transplantations has been increased, the
number of available donor lung grafts is still a main limitation
factor in this treatment option resulting in waiting list mortality.
Despite sophisticated mechanical ventilator techniques on
the intensive care unit (ICU) for patients awaiting a suitable lung
graft, refractory hypercapnia, or hypoxemia might develop.2
For these patients, extracorporeal life support (ECLS) is the only
chance to survive until a lung graft becomes available.2
Although the early experience with extracorporeal mem-
brane oxygenation (ECMO) as a bridge to lung transplanta-
tion was discouraging, improvements in artificial lung device
technologies have made it possible to bridge these patients
successfully to lung transplantation.2,3 Recent studies using
ECLS as a bridge to LuTx have reported comparable short-
and mid-term results to recipients undergoing LuTx without
preoperative ECLS.4-23
We describe our experience with ECLS technologies mainly
ECMO as a bridge to lung transplantation in patients with
refractory respiratory failure.
METHODS
We performed a retrospective review of prospectively col-
lected data of all recipients undergoing ECLS with either
ECMO or interventional lung assist (iLA) as a bridge to lung
transplantation from January 2007 toOctober 2013 at Zurich
University Hospital. Bridged recipients (ECLS group, N = 26)
were compared with recipients that underwent LuTx without
preoperative ECLS (control group, N = 160). Censor date for
survival analysis was April 22, 2014.
Data Analysis
Statistical analysis was performed using the Statistical Pack-
age for the Social Science version 21.0 (SPSS IBM, New York,
NY). Continuous variables are shown as mean ± standard
deviation ormedian (range or interquartile ranges). The non-
parametric Mann-Whitney test was used to compare inde-
pendent continuous variables between the 2 groups. The
Fischer exact test was used to determine the association
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between 2 categorical variables. Kaplan-Meier analysis
was used to calculate actuarial survival. The log-rank test
was used to test the difference in Kaplan-Meier survival
curve between the groups. A P value of 0.05 or less was
considered as statistical significance.
RESULTS
During the study period, 186 lung transplantations were
performed, 26 (13.9%) received ECLS (ECMO or iLA) be-
fore transplantation (ECLS group), and 160 had no sup-
port before transplantation (control group). An additional
4 patients were placed on ECMOwith the intention to trans-
plant, but 2 died and 2weaned from ECMOand successfully
transplanted.
Two patients failed bridge to transplant on ECMO while
waiting an available lung graft. One patient with idiopathic
pulmonary fibrosis (IPF) diagnosis died due to heart failure,
and the other cystic fibrosis (CF) patient died due to sepsis
and multiorgan failure. Therefore, our bridge to transplant
success rate was 86.6% (26/30). The indications for ECLS
were respiratory insufficiency due to chronic lung allograft
dysfunction (N = 1), primary graft dysfunction (N= 2), hyper-
capnia and right heart failure (N = 4), hypercapnia (N = 9),
and hypercapnia and hypoxemia (N = 10). The type of ECLS
was venovenous ECMO (VV ECMO) (n = 10), venoarterial
ECMO (n = 4), iLA (n = 5), and stepwise combination of
them (n = 7). In VV ECMO, the femoral vein and internal
jugular vein were the most common cannulation sites. In
12 cases, we used dual lumen catheter (Avalon; MAQUET
Cardiopulmonary AG, Rastatt, Germany) for VV ECMO.
In VA ECMO, femoral vein-femoral artery, internal jugular
vein-femoral arteries, axillary artery-femoral vein were the
most common cannulation sites. In 2 patients with iLA, one
was on Novalung (Novalung GmbH, Heilbronn, Germany)
femoral artery-femoral vein, the other was on ProLung
(Estor S.P.A, Milano, Italy) cannulated via the internal jugu-
lar vein (Sheldon Catheter).
To prevent limb ischemia and local complications with
peripheral cannulation, we use a synthetic vascular graft
(8 mm) in end-to-side anastomosis fashion to the femoral
or axillary artery, which is passed through a separate skin in-
cision. The arterial cannula is passed through the vascular
graft until the tip of the cannula reached the anastomosis
and pointed to the proximal site of the artery.
The median duration of pretransplant ECLS support was
21 days (range, 1-81). In our series, 20 patients were sedated
andmechanically ventilated while they were at the same time
on ECLS. The median duration of mechanical ventilation
before ECLSwas 2.5 days (range, 1-35). Recipient age, recip-
ient sex, donor age, and donor sex were comparable between
pretransplant ECLS group and control group (Table 1). One
patient developed heparin-induced thrombocytopenia dur-
ing bridging. This patient successfully underwent unilateral
lung transplantation. Cystic fibrosis (46.1%) was the most
common diagnosis in the pretransplant ECLS group followed
by idiopathic pulmonary fibrosis (38.4%) (Table 2). One pa-
tient received lung from donation after cardiac death donor,
and 1 patient received unilateral lobar lung retransplantation
after ex vivo lung evaluation.
In the pretransplant ECLS group, 88.4% (23/26) of the
recipients underwent bilateral lung transplantation, whereas
95.6% (153/160) of the patients in the control group
underwent bilateral lung transplants (P = 0.14). The rate of
retransplantations was comparable between the groups
(P = 0.16) (Table 1). Sixty-one percent of the recipients in
the pretransplant ECLS group and 47.5% in the control
group underwent size reduction during the transplantation
(P = 0.14). Cadaveric lobar lung transplantation was per-
formed in 13 recipients in the pretransplant ECLS group
and in 54 recipients in the control group. During the trans-
plant procedure, ECMO was used in ECLS group, whereas
only 47.5% (76/160) of the patients required ECMO or car-
diopulmonary bypass in the control group. The cold ischemic
times were comparable between the 2 groups (Table 1).
Posttransplant ECMO support was necessary in 14 of
26 patients in the pretransplant ECLS group with a median
of 2 days (range, 1-9). The intubation time and ICU staywere
significantly longer in the pretransplant ECLS group com-
pared with the control group (P = 0.001) (Table 1).
The complications related to ECMO for ECLS group are
shown in Table 3. Tracheostomywas required in 19 (11 have
already had tracheostomy on the ICU) of 26 patients (73%),
whereas 27.5% (44/160) required tracheostomy in the con-
trol group (P = 0.001) (Table 4). The rate of primary graft
dysfunction grade 2 or 3 at 72 hours as defined by the In-
ternational Society for Heart and Lung Transplantation24
was 23% (6/26) in the pretransplant ECLS group compared
TABLE 1.
Patient characteristics
ECLS group Control group P
N 26 160
Recipient age, y 44.5 (14-65) 56 (10-70) 0.6
Recipient sex (m/f) 12/14 85/75 0.5
Waiting list time, d 31 (5-1965) 196 (1-914) 0.4
Donor age, y 43 (13-74) 50 (11-81) 0.4




Retransplantation 4 6 0.2
Size reduction 16 76 0.8
Lobar transplant 13 54
ECMO/CPB use 26 76 0.001
Cold ischemic time
Right lung, min 278 ± 104 250 ± 97 0.2
Left lung, min 359 ± 80 334 ± 100 0.2
Intubation time, d 6 (IQR, 1-23) 1 (IQR, 1-2) 0.001
ICU stay, d 18 (IQR, 3-38) 3 (IQR, 2-10) 0.001
Data presented as median (range or IQR) or mean ± standard deviation.
CPB, cardiopulmonary bypass; IQR, interquartile ranges.
TABLE 2.
Diagnosis
ECLS group (N = 26) Control group (N = 160)





COPD, chronic obstructive pulmonary disease; PPH, primary pulmonary hypertension.
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to 15.6% (25/160) in the control group (P = 0.36). In the
pretransplant ECLS group, 34.6% of the patients underwent
early rethoracotomy (<10 days) for hemothorax (Table 4).
In the ECLS group, 11 of 26 patients (42.3%) required renal
replacement therapy, and 53.8% developed critical illness
myopathy, compared to 15.6% and 2.5%, respectively, in
the control group. There were no bronchial anastomotic
complications in the pretransplant ECLS group, whereas only
2 patients in the control group underwent surgery for bron-
chial anastomotic complication at days 5 and 12.
The 30-day mortality in the pretransplant ECLS group
was 11.5% (3/26) and 3.7% (6/160) in the control group
(P = 0.1). The causes of early mortality in control group were
hemorrhagic shock in 1, sepsis/MOF in 1, intracranial bleed-
ing in 2, and severe graft dysfunction in 2 patients. For ECLS
group, the causes were refractory cardiogenic shock with
intra-abdominal and intrathoracic bleeding in 2 and sepsis
and multiorgan failure in 1. The median age for 30-day mor-
tality was 58 years (range, 29-60) for the ECLS group and
65 years (range, 57-70) for the control group.
The rate of late mortality (>3 months) in the control group
was 22% (35/160) and 23% (6/26) in the ECLS group. The
causes of late mortality are shown in Table 5.
Unadjusted 30-day, 1-year, and 2-year survivals were
89%, 68%, and 53%, respectively, for bridged patients and
96%, 85%, and 79%, respectively, in the control group
(P = 0.001, log rank) (Figure 1). Ninety-day conditional sur-
vivals were 89% and 69% at 1 and 2 years for ECLS group,
compared to 92% and 86% for control group (P = 0.03). In
CF patients (N = 12), 1-year and 2-year survival rates were
82%, whereas it was 50% and 25%, respectively, for IPF
recipients.
All of the 6 patients that were bridged to lung transplanta-
tion on awake ECMO are still alive with a median follow-up
of 10.8 months (range, 6-21 months).
DISCUSSION
This is a large single-center experience of the use of pre-
transplant ECLS, mostly ECMO, as a bridge to lung trans-
plantation over a 7-year period (2007-2013). At our center,
pretransplant ECLS constituted approximately 14% (26/186)
of our transplant experience in that period of time, which is
the largest percentage among reported series from large trans-
plant centers.10,13,20 In 2013, this rate was 35.7%of our over-
all lung transplant activity, which reflects the high number of
urgent recipients undergoing lung transplantation.
Because of improved technologies, the transplant candi-
dates can tolerate ECMO for longer periods of time; however,
because of several reasons, such as muscular deconditioning of
the patients, hemolysis, bleeding, infection, and stroke, systemic
or pulmonary thromboembolism shorter bridging time brings
TABLE 4.
Postoperative complications
ECLS group Control group P
No 26 160
Tracheostomy 19 44 0.001
Thoracic hernia 0 6 0.3
Lymphocele 4 10 0.2
PGD 2/3 at T72 6 25 0.4
Hemothorax 12 30 0.03
Early (<10 d) 9 16
Late (>10 d) 3 14
Abdominal complication 0 15 0.8
Phrenic nerve injury 1 1 0.1
Dialysis 11 25 0.001
Technical complication 1 4 0.6
Critical illness myopathy 14 4 0.001
PGD, Primary graft dysfunction grade 2 or 3 at time 72 hours.
TABLE 5.
Causes of late (>3 months) mortality
Control group (N) ECLS group (N)
Sepsis/multiorgan failure 14 4
Intracranial bleeding 2 —
Heart failure 1 —
Malignancy 4 —
BOS 11 —
Renal failure — 1
Unknown 3 1
BOS, bronchiolitis obliterans syndrome.
TABLE 3.
Complications of related to ECMO cannulation
N %
Infection 1 6.3
Bleeding + infection 3 18.8
Thrombosis 3 18.8
Lymphocele 4 6.3
Brachial plexus injury 1 6.3
FIGURE 1. Cumulative survival curve that compares control group
versus pretransplantation ECLS group. Number at risk:
Months 0 12 24 36 48 60
Control 180 130 97 65 43 25
Pre-Tx ECLS 26 12 7 2 1 1
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better outcomes.8,10 Median support time reported in the liter-
ature varies from 3 to 17 days (range, 1-229).4-6,8-14,16,17,21-23
Our median support time was 21 days (range, 1-81) which is
longer than in all reported series. To demonstrate the possible
effect of ECLS time on outcomes, Crotti et al8 analyzed survival
dividing patients according to their waiting time on ECMO as
early (14 days) and late (>14 days). This group demonstrated
significantly better 1-year survival (82%) in the early study
group compared to late study group (29%).8 Our results (not
shown in Results section) are in contrast to the data reported
by Crotti et al. Our “late” patients' survival was superior com-
pared to the “early” patients, although the difference was not
statistically significant. In our series, 1-year and 2-year survival
was 67%and50% in the early group (N= 9), respectively, com-
pared to 74% and 59% in the late group (N = 17) (P = 0.29).
Although the numbers are small to draw any final conclu-
sions, the reasons for that might be the higher percentage
of CF recipients (9 vs 3) and patients on awake ECMO
(4 vs 2) in the “late” ECMO group compared to the “early”
ECMO group.
In patients requiring pretransplant ECLS, high rates of pri-
mary graft dysfunction have been reported.10-20 The reasons,
although not clear, for higher rates of primary graft dysfunc-
tion include the systemic inflammatory status and coagulop-
athy, requiring more blood transfusions.10,14 We transferred
14 patients to the ICU with ECMO. The reason for that is
not only primary graft dysfunction. In our center, patients
who were on ECMO for a long time with secondary pulmo-
nary arterial hypertension, or right heart failure, were not
removed from ECMO at the operating room after the trans-
plantation. We give them time to recover, especially, the car-
diac function. On the other hand, in a patient who is on VV
ECMO only for hypercapnia, we remove the ECMO in the
operating room if the graft function is good.
An important development in the field of bridging patients
on ECLS is the concept of awake and ambulatory ECMO.
The Hannover Group based on their clinical success in
patients with pulmonary hypertension and end-stage right
ventricular failure adopted this strategy for other forms of
end-stage lung diseases.14,25 Themain advantage of the awake
ECMO concept is the avoidance of complications and draw-
backs associated with sedation, intubation, and long-term
ventilation.14,25 Prolonged mechanical ventilation results
in nasocomial infection rate, critical illness myopathy, lead-
ing to difficult and prolonged weaning after transplantation,
resulting in longer ventilation and ICU stay after transplanta-
tion than those in the awake ECMO group.4,14,25 The Goth-
enburg Group reported 40% critical illness myopathy in
their cohort which resulted in longer ICU and hospital stay.4
In our series, critical illness myopathy occurred in 54%
(14 of 26) of patients resulting in significantly longer ICU
stay and intubation time compared to control group. The
6-month survival rate reported by Hannover Group in pa-
tients on awake ECMO who reached transplantation was
80%.14We successfully bridged 6 patients to transplantation
on awake ECMO, and all of them are alive with a median
follow-up of 10.8 months (range, 6-21). Awake ECMO
should be aimed for in any case possible to obtain better
posttransplant outcomes. Our number is very low to draw
a strong conclusion, and our observation in these groups of
patients corresponds to other publications that favor this
mode of bridging.14
One- and 2-year survival rates for bridged patients vary
between 33% to 100%and 60% to 100% in published series
(Table 6).4-6,8-14,16,17,21-23 Our 2-year survival is somehow
lower than the reported series but we think that these high-
risk patients would have 100%mortality rate without trans-
plant. Our 3-month conditional survivals were 89%and 69%
at 1 and 2 years for ECLS group, which seems acceptable in
this high-risk group. In addition, the type of pretransplant
diagnosis is very important. In our series, CF recipients had
82% 1- and 2-year survival rates compared to 50% and
25% for IPF recipients, respectively. Most of the reported se-
ries have unfortunately not reported in detail survival rates
related to diagnosis. The French Group reported 2-year sur-
vival rate of 71% in CF and 42.9% in IPF recipients, show-
ing a survival advantage for CF recipients.6 Although the
experience is limited, the underlying diagnosis for bridging
TABLE 6.
Experience with ECLS as a bridge to lung transplant (series with more than 7 cases)
Author Year Reference N % Tx Activity With ECLS ECLS Duration Mode of ECLS Bridge % 30 d surv 1-y surv 2-y surv CF, % IPF, %
Toyoda et al10 24 3,4 91 h (171-242) VV VA 77,4 88 74 74 21 33
Fuehner et al14 16 NA 9 d (1-45) VV VA 61,5 NA 80* NA 19 35
Bermudez et al16 17 1,3 3,3 d (1-49) VV VA NA 81 74 NA 23 35
Lafarge et al6 30 (9 centers) NA 3,5 d (0-11) VV VA 83 80 66,5 60,5 56 30
Dellgren et al4 16 NA 9 d (1-229) VV VA 80 81 75 70 15 60
Hoopes et al9 31 (2 centers) NA 13,7 d (2-53) VV VA NA NA 93 80 20 42
Hämmäimen et al17 13 (2 centers) NA 17 d (1-59) VV VA 81 NA 92 NA 8 37
Lang et al13 34 NA 4,5 d (1-63) VV VA, iLA 89 NA 60 NA 44 23
Bittner et al12 9 NA 6 h to 15 d iLA VV VA NA 63 33 NA 33 22
Anile et al5 7 3,5 Mean d 6 ± 2,1 VV VA 58,3 100 87,5 NA 85 —
Javidfar et al11 10 4 6 d (3,5-18) VV VA 56 100 100 100 NA NA
Puri et al23 10 2,9 32 h (0-1048) VV VA 62,5 NA 33 NA 7 —
Cypel et al21 12 NA Mean 7 d VV VA, iLA 100 100 83
Crotti S et al8 17 (2 centers) NA 1-51 d VV VA 68 NA 76 24 35
Fischer et al22 12 6,8 Mean 15 d (4_32) iLA 83 80 80 NA 16 33
Zurich, present series 2014 26 14 21 d (1-81) VV VA, iLA 86 89 68 53 46 38
Tx, transplantation; VA, venoarterial; NA, not available; surv, survival.
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such patients should be taken into consideration, and poten-
tial candidates for bridging to transplantation are selected
very carefully. The expectation after bridge to transplanta-
tion should be, of course, an outcome comparable to those
who did not need ECLS before transplantation. When we
refer to the literature, we can see that 1-year and 2-year sur-
vival rates range between 33% to 100% and 60% to 100%,
respectively (Table 6). The centers with low 1-year survival
rates, however, did not publish their 2-year survival rates
which makes comparison difficult for us. Underlying disease
is an important factor affecting the outcome. We know that
CF patients do better than other diagnosis, especially better
than IPF patients who usually have secondary pulmonary
hypertension.
In our series, 20 patients were sedated and mechanically
ventilated while they were at the same time on ECLS. The
outcomes are poor if these patients are paralyzed and me-
chanically supported. This might be one of the explanations
of our poor outcomes. Of 12CF patients, 2 were awake while
on ECLS. This might be a reason of poor outcome even for
CF cases.
Our study has several limitations. This is a single-center
retrospective study using a historical control group. Although
we included 26 patients, the number of study patients is
still low.
In conclusion, the present data add to the available data
and highlight the risks that we suspected based on clinical
intuition. Our data show significantly lower survival in this
high-risk group compared to those transplanted without pre-
operative ECLS. The underlying diagnosis should be taken
into consideration when selecting candidates. Awake and
ambulatory ECMO provides a superior prognosis for these
patients and should be aimed for whenever possible. The
literature will grow in this field by continually tracking case
series like this in a registry. Continuing to revisit data in a reg-
istry formatwill help guide patient selection andmanagement.
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